BioSpace News Archive

In response to Hurricane Sally, which has led the governors of Alabama , Florida , Louisiana , and Mississippi to declare states of emergency, Blue Cross Blue Shield of Massachusetts (Blue Cross), Inc. is expediting access to care for affected members.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, where they will discuss Surface Oncology’s lead programs, SRF6

Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research announced today the results from the largest Phase 3 lupus nephritis clinical trial ever conducted.

The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug BenlystaR (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney.

Akerna (Nasdaq: KERN), a leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), today announced the release of MJ Analytics, a next generation cannabis data analytics platform.

UTHealth transplant surgeons at Memorial Hermann were the first in Texas to perform a double lung transplant on a 70-year-old man whose lungs were severely damaged by COVID-19.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an R&D Day on Wednesday, September 30, 2020. The event is scheduled to take place from 10:00 a.m. to 12:30 p.m. ET in a virtual format.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the company will present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21st at 1:40 p.m. ET.

- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC [16-September-2020] SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the EL

Dr. Hugh-Jones brings 20 years of global biopharmaceutical industry experience to his new post as Volastra’s CEO